

PRESS RELEASE

Intendis and Valeant sign distribution agreement for Finacea®, a new treatment in the UK for rosacea

Berlin, 04 October 2006

Intendis GmbH and Valeant Pharmaceuticals Ltd., Basingstoke, have signed a distribution agreement for the sale of a range of Intendis products in the United Kingdom. This includes Finacea®, a new topical treatment for the treatment of rosacea, which will be launched to medical professionals this week.

The agreement came into effect on September 1, 2006 and is part of the strategy to further expand the presence of Intendis in those markets where the company does not have its own subsidiaries. "This agreement with Valeant offers us good opportunities for growth in one of the world's largest dermatology markets", emphasised Professor Wolfgang Kehr, CEO of Intendis GmbH. Valeant will serve the market with a dedicated specialist dermatology sales and marketing organisation. "We are delighted to now be better able to offer our products to doctors and patients in the UK. With Valeant, we have found a competent partner with excellent knowledge of this market", said Kehr.

Colin Terry, Managing Director of Valeant Pharmaceuticals UK, is delighted with the agreement. "Valeant already has a strong dermatology portfolio in the UK with Dermatix® - a market leader in scar prevention and Efudix® – a leading brand for actinic keratoses, explains Colin. "This agreement expands our product portfolio and offer clinicians a range of treatments for many dermatological conditions."

The Intendis portfolio that Valeant will sell in UK comprises not only Finacea® (15 % azelaic acid gel), which is the rosacea treatment most frequently prescribed by American dermatologists, but also the 30g formulation of Skinoren® Cream (20% azelaic acid cream) used in the treatment of acne. In addition the portfolio will include Scheriproct®, a treatment for haemorrhoids, available as an ointment (30g) or a pack of 12 suppositories, as well as Ultrabase®, a moisturising cream available in a 50g tube or a 500g pump dispenser.

Intendis is a fully integrated pharmaceutical company – dedicated to dermatology. Intendis is focused on the development, manufacturing and marketing of high quality, innovative topical and systemic therapies, targeted to treat skin disorders. The current product portfolio comprises treatments of eczema disorders including atopic dermatitis, as well as psoriasis, acne, rosacea and fungal skin infections (mycoses). Intendis markets a number of successful brands such as Advantan® and Nerisona® for the treatment of eczema, Travocort® (dermatomycoses), Skinoren® (acne), Finacea® (rosacea) and Psorcutan® and Psorcutan® Beta (psoriasis). The company's objective is to become a leading partner in the field of dermatology. Intendis GmbH is a wholly-owned subsidiary of Schering AG, Germany.

This press release has been published by Corporate Communication of Intendis GmbH, Berlin, Germany.

Your contact at Corporate Communication:

Sven Winkler, T: +49 30 52 00 75 650; media@intendis.com

Find additional information at: www.intendis.com

Certain statements in this press release that are neither reported financial results nor other historical information are forward-looking statements, including but not limited to, statements that are predictions of or indicate future events, trends, plans or objectives. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results and Intendis' plans and objectives to differ materially from those expressed or implied in the forward-looking statements. Intendis GmbH undertakes no obligation to update publicly or revise any of these forward-looking statements, whether to reflect new information or future events or circumstances or otherwise.